IN2015DN02807A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02807A
IN2015DN02807A IN2807DEN2015A IN2015DN02807A IN 2015DN02807 A IN2015DN02807 A IN 2015DN02807A IN 2807DEN2015 A IN2807DEN2015 A IN 2807DEN2015A IN 2015DN02807 A IN2015DN02807 A IN 2015DN02807A
Authority
IN
India
Prior art keywords
crystalline phase
absd
disulfanediylbis
aminobutane
lysine
Prior art date
Application number
Other languages
English (en)
Inventor
Fabrice; Balavoine
Jean-Marie; Schneider
Gerard; Coquerel
Nicolas; Couvrat
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of IN2015DN02807A publication Critical patent/IN2015DN02807A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26—Separation; Purification; Stabilisation; Use of additives
    • C07C319/28—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2807DEN2015 2012-10-22 2013-10-22 IN2015DN02807A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306307.5A EP2722327A1 (en) 2012-10-22 2012-10-22 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
PCT/EP2013/072028 WO2014064077A1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine

Publications (1)

Publication Number Publication Date
IN2015DN02807A true IN2015DN02807A (cg-RX-API-DMAC7.html) 2015-09-11

Family

ID=47278723

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2807DEN2015 IN2015DN02807A (cg-RX-API-DMAC7.html) 2012-10-22 2013-10-22

Country Status (30)

Country Link
US (2) US9278921B2 (cg-RX-API-DMAC7.html)
EP (2) EP2722327A1 (cg-RX-API-DMAC7.html)
JP (1) JP6317358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102103407B1 (cg-RX-API-DMAC7.html)
CN (1) CN104768927B (cg-RX-API-DMAC7.html)
AR (1) AR093070A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013336738B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008931B1 (cg-RX-API-DMAC7.html)
CA (1) CA2884914C (cg-RX-API-DMAC7.html)
CY (1) CY1119913T1 (cg-RX-API-DMAC7.html)
DK (1) DK2909169T3 (cg-RX-API-DMAC7.html)
EA (1) EA024460B1 (cg-RX-API-DMAC7.html)
ES (1) ES2658413T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180189T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036037T2 (cg-RX-API-DMAC7.html)
IL (1) IL237733B (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02807A (cg-RX-API-DMAC7.html)
LT (1) LT2909169T (cg-RX-API-DMAC7.html)
ME (1) ME02955B (cg-RX-API-DMAC7.html)
MX (1) MX353693B (cg-RX-API-DMAC7.html)
NO (1) NO2909169T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ706070A (cg-RX-API-DMAC7.html)
PL (1) PL2909169T3 (cg-RX-API-DMAC7.html)
PT (1) PT2909169T (cg-RX-API-DMAC7.html)
RS (1) RS56896B1 (cg-RX-API-DMAC7.html)
SI (1) SI2909169T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800086T1 (cg-RX-API-DMAC7.html)
TW (1) TWI643842B (cg-RX-API-DMAC7.html)
WO (1) WO2014064077A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503574B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951562B (zh) * 2014-05-09 2016-04-20 四川九章生物化工科技发展有限公司 一种绿原酸晶型及其制备方法
WO2022225712A1 (en) * 2021-04-22 2022-10-27 Teva Pharmaceuticals International Gmbh Solid state forms of firibastat and processes for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235687B2 (en) * 2002-07-16 2007-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2439192A1 (en) 2010-10-07 2012-04-11 Quantum Genomics Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)
US9447050B2 (en) * 2011-04-05 2016-09-20 The Translational Genomics Research Institute Solid forms of curcumin

Also Published As

Publication number Publication date
PL2909169T3 (pl) 2018-07-31
KR20150072454A (ko) 2015-06-29
RS56896B1 (sr) 2018-04-30
US9278921B2 (en) 2016-03-08
NO2909169T3 (cg-RX-API-DMAC7.html) 2018-06-02
BR112015008931A2 (pt) 2017-07-04
CA2884914C (en) 2021-01-05
JP6317358B2 (ja) 2018-04-25
TW201418202A (zh) 2014-05-16
HRP20180189T1 (hr) 2018-04-20
AR093070A1 (es) 2015-05-13
HK1212321A1 (en) 2016-06-10
DK2909169T3 (en) 2018-02-26
PT2909169T (pt) 2018-02-26
US20160221940A1 (en) 2016-08-04
SI2909169T1 (en) 2018-04-30
ES2658413T3 (es) 2018-03-09
MX353693B (es) 2018-01-24
CN104768927B (zh) 2017-06-09
US20150284325A1 (en) 2015-10-08
MX2015005059A (es) 2015-11-23
EP2722327A1 (en) 2014-04-23
AU2013336738B2 (en) 2017-05-18
HUE036037T2 (hu) 2018-06-28
ME02955B (me) 2018-07-20
CA2884914A1 (en) 2014-05-01
EA201500438A1 (ru) 2015-09-30
KR102103407B1 (ko) 2020-04-22
NZ706070A (en) 2018-11-30
SMT201800086T1 (it) 2018-05-02
WO2014064077A1 (en) 2014-05-01
IL237733B (en) 2019-03-31
EP2909169A1 (en) 2015-08-26
LT2909169T (lt) 2018-04-25
CN104768927A (zh) 2015-07-08
BR112015008931B1 (pt) 2021-05-18
CY1119913T1 (el) 2018-06-27
TWI643842B (zh) 2018-12-11
AU2013336738A1 (en) 2015-04-09
EA024460B1 (ru) 2016-09-30
ZA201503574B (en) 2016-01-27
EP2909169B1 (en) 2018-01-03
JP2015536316A (ja) 2015-12-21
US9487477B2 (en) 2016-11-08

Similar Documents

Publication Publication Date Title
CY1120805T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2015003021A (es) Derivados de acido glicirretinico y metodos de uso de los mismos.
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
HK1211947A1 (en) Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
MY172574A (en) Dicaffeoylquinic acid-containing drink
IN2011KN05169A (cg-RX-API-DMAC7.html)
HK1201067A1 (en) Sialic acid analogs
MX353693B (es) Fase cristalina de (3s,3s&#39;) 4,4&#39;-disulfanodiilbis (ácido 3-aminobutano-1-sulfónico) con l-lisina.
CA2901220C (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
WO2012150607A3 (en) Oral liquid composition comprising divalproex sodium and process for preparing thereof
MY181682A (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it
WO2011152657A3 (en) Acetyl-l-carnitine malate, process for preparing the same, and pharmaceutical composition comprising the same
TN2014000106A1 (en) Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
WO2013064326A3 (de) Arjunolsäure zur erhöhung der sebumproduktion
MX2012013055A (es) Un procedimiento mejorado para purificar el complejo de cloruro de benzalconio-dialil oxido de disulfuro modificado y usos.
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
UA99014C2 (ru) Метиловый эстер n-[(2-оксоиндолинилиден-3)-2-оксиацетил]аминоуксусной кислоты, который проявляет противовоспалительное действие
UA105665C2 (uk) 3-метиламіносукциноїламідо-n-(3&#39;,4&#39;-диметилфеніл)антранілова кислота, що проявляє протизапальну, анальгетичну, діуретичну та протигрибкову активність